Study Evaluating the Use of a New Drug with Hormone Therapy for Breast Cancer

What we are studying

The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney or breast cancer. It is considered investigational for non-metastatic breast cancer patients. In this study you will get hormone treatment with either everolimus or with placebo (a pill with no medication). The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.

Who is Eligible

  • Genders:
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Non-Metastatic Breast Cancer
  • Completed surgery
  • ER/PR positive
  • HER2 negative

What is involved

  • Physical exams & Blood test which are part of your regular care
  • Complete daily study drug diary
  • Study pills daily for up to 54 weeks



Contact Information

Study Coordinator
Stacey Lewis

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.